Sonja Witteveen, MD, The Netherlands Cancer Institute, Amsterdam, Netherlands, describes a multicenter real-world analysis of neoadjuvant ipilimumab plus nivolumab in resectable stage III melanoma, comparing treatment-naïve patients with those recurring after adjuvant PD-1 blockade, a group excluded from the NADINA (NCT04949113) trial. Pretreated patients had lower major pathologic response rates and event-free survival, particularly those recurring early after adjuvant therapy. However, patients achieving a major pathologic response had equally excellent outcomes regardless of prior treatment, suggesting potential efficacy of this approach in pretreated patients, especially those with later recurrences. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.